CAR‐CD19 T cells have shown exciting results in the treatment of pediatric hematologic malignancies.8 Due to the histological structural characteristics of solid tumors, the absence of specific antigens, clinical results for solid tumors have not been remarkable. The gene discussed is CD19; the disease is cancer.